Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma

Table 2 Tumor response based on mRECIST guidelines

Time point	Lesion diameter (cm), mean ± standard deviation	Number with available data (N = 97)	mRECIST*, n (%)
Time point	Lesion diameter (cm), mean ± standard deviation	Number with available data (N = 97)	CR	PR	SD	PD
Baseline	10.2 ± 3.5	97	–	–	–	–
3 months	8.2 ± 3.5	87	10 (11.5)	42 (48.3)	19 (21.8)	16 (18.4)
6 months	6.9 ± 3.3	64	12 (18.8)	23 (35.9)	8 (12.5)	21 (32.8)

*mRECIST, Response Evaluation Criteria In Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease

ISSN: 1471-230X